Biocodex

Biocodex is privately owned by the founding family. The company's CEO, Jean-Pierre Tabet, leads day-to-day operations, and the board reflects family control. No external shareholders or private equity investors hold a stake (public record).

Biocodex functions as an integrated entity: the family's wealth is generated by and managed within the pharmaceutical company. There is no publicly disclosed separate family office. The firm reinvests profits into R&D, acquisitions, and international expansion, effectively serving as a single-family office through its corporate structure (public record).

The firm specializes in microbiome science, particularly probiotics and gastrointestinal health. Its flagship product, Floré, is one of the most widely distributed probiotics globally. Biocodex also markets prescription medications for pain and central nervous system disorders (public record).

Yes, Biocodex acquired the U.S. probiotic brand Culturelle in 2014 from i-Health Inc., marking a significant expansion into the North American market. The company has pursued other targeted acquisitions to broaden its product pipeline and geographic reach (per public record).

Headquartered in Gentilly, France, Biocodex operates in over 100 countries, with manufacturing in France and commercial offices across Europe, Asia, Africa, and the Americas. The firm has a particularly strong presence in European and North American markets (public record).

The firm invests heavily in clinical research for microbiome-based therapeutics. It conducts its own R&D and collaborates with academic institutions and research organizations globally. Recent efforts have focused on expanding the evidence base for probiotics in immune and digestive health (public record).